{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:42:14Z","timestamp":1792456934156,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.bmc.2021.116497","type":"journal-article","created":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T11:40:42Z","timestamp":1636544442000},"page":"116497","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Site-specific construction of triptolide-based antibody-drug conjugates"],"prefix":"10.1016","volume":"51","author":[{"given":"Ding","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurong","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zili","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiakang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiusheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongli","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2021.116497_b0005","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920962997","article-title":"An overview of antibody-drug conjugates in oncological practice","volume":"12","author":"Theocharopoulos","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"5","key":"10.1016\/j.bmc.2021.116497_b0010","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"10.1016\/j.bmc.2021.116497_b0015","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.drudis.2013.11.004","article-title":"Antibody-drug conjugates: current status and future directions","volume":"19","author":"Perez","year":"2014","journal-title":"Drug Discov Today"},{"issue":"1","key":"10.1016\/j.bmc.2021.116497_b0020","doi-asserted-by":"crossref","first-page":"1951427","DOI":"10.1080\/19420862.2021.1951427","article-title":"Targeting cancer with antibody-drug conjugates: Promises and challenges","volume":"13","author":"Dean","year":"2021","journal-title":"MAbs"},{"issue":"15","key":"10.1016\/j.bmc.2021.116497_b0025","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1002\/anie.201307628","article-title":"Antibody-drug conjugates: an emerging concept in cancer therapy","volume":"53","author":"Chari","year":"2014","journal-title":"Angew Chem Int Ed Engl"},{"issue":"1","key":"10.1016\/j.bmc.2021.116497_b0030","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1021\/acs.accounts.8b00537","article-title":"Total Synthesis in Search of Potent Antibody-Drug Conjugate Payloads. From the Fundamentals to the Translational","volume":"52","author":"Nicolaou","year":"2019","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.bmc.2021.116497_b0035","doi-asserted-by":"crossref","first-page":"111682","DOI":"10.1016\/j.ejmech.2019.111682","article-title":"Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985)","volume":"183","author":"Xu","year":"2019","journal-title":"Eur J Med Chem"},{"issue":"19","key":"10.1016\/j.bmc.2021.116497_b0040","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1002\/cncr.30789","article-title":"Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics","volume":"123","author":"Ocean","year":"2017","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.bmc.2021.116497_b0045","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1039\/D0NP00054J","article-title":"Triptolide: reflections on two decades of research and prospects for the future","volume":"38","author":"Tong","year":"2021","journal-title":"Nat Prod Rep"},{"issue":"10","key":"10.1016\/j.bmc.2021.116497_b0050","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1158\/1535-7163.MCT-09-0549","article-title":"Triptolide is an inhibitor of RNA polymerase I and II-dependent transcription leading predominantly to down-regulation of short-lived mRNA","volume":"8","author":"Visp\u00e9","year":"2009","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"10.1016\/j.bmc.2021.116497_b0055","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.3390\/cancers11081138","article-title":"Novel Antibody-Drug Conjugate with Anti-CD26 Humanized Monoclonal Antibody and Transcription Factor IIH (TFIIH) Inhibitor, Triptolide, Inhibits Tumor Growth via Impairing mRNA Synthesis","volume":"11","author":"Hayashi","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bmc.2021.116497_b0060","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.omto.2020.07.001","article-title":"Cetuximab-Triptolide Conjugate Suppresses the Growth of EGFR-Overexpressing Lung Cancers through Targeting RNA Polymerase II","volume":"18","author":"Zhang","year":"2020","journal-title":"Mol Ther Oncolytics"},{"issue":"2","key":"10.1016\/j.bmc.2021.116497_b0065","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1039\/D0CS00310G","article-title":"Site-selective modification strategies in antibody-drug conjugates","volume":"50","author":"Walsh","year":"2021","journal-title":"Chem Soc Rev"},{"issue":"2","key":"10.1016\/j.bmc.2021.116497_b0070","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nchem.2393","article-title":"Site-selective protein-modification chemistry for basic biology and drug development","volume":"8","author":"Krall","year":"2016","journal-title":"Nat Chem"},{"issue":"2","key":"10.1016\/j.bmc.2021.116497_b0075","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nchem.2415","article-title":"Recent advances in the construction of antibody-drug conjugates","volume":"8","author":"Chudasama","year":"2016","journal-title":"Nat Chem"},{"key":"10.1016\/j.bmc.2021.116497_b0080","doi-asserted-by":"crossref","first-page":"113355","DOI":"10.1016\/j.ejmech.2021.113355","article-title":"Combretastatin A4-derived payloads for antibody-drug conjugates","volume":"216","author":"Huang","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2021.116497_b0085","doi-asserted-by":"crossref","first-page":"112080","DOI":"10.1016\/j.ejmech.2020.112080","article-title":"Bis(vinylsulfonyl)piperazines as efficient linkers for highly homogeneous antibody-drug conjugates","volume":"190","author":"Huang","year":"2020","journal-title":"Eur J Med Chem"},{"issue":"23","key":"10.1016\/j.bmc.2021.116497_b0090","doi-asserted-by":"crossref","first-page":"115793","DOI":"10.1016\/j.bmc.2020.115793","article-title":"Divinylsulfonamides enable the construction of homogeneous antibody-drug conjugates","volume":"28","author":"Huang","year":"2020","journal-title":"Bioorg Med Chem"},{"issue":"18","key":"10.1016\/j.bmc.2021.116497_b0095","doi-asserted-by":"crossref","first-page":"4972","DOI":"10.1021\/acs.orglett.7b02464","article-title":"Divinylsulfonamides as Specific Linkers for Stapling Disulfide Bonds in Peptides","volume":"19","author":"Li","year":"2017","journal-title":"Org Lett"},{"issue":"1","key":"10.1016\/j.bmc.2021.116497_b0100","article-title":"Construction of paclitaxel-based antibody-drug conjugates with a PEGylated linker to achieve superior therapeutic index","volume":"5","author":"Shao","year":"2020","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"10.1016\/j.bmc.2021.116497_b0105","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nbt.3212","article-title":"Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index","volume":"33","author":"Lyon","year":"2015","journal-title":"Nat Biotechnol"},{"issue":"10","key":"10.1016\/j.bmc.2021.116497_b0110","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1021\/jm2002958","article-title":"Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates","volume":"54","author":"Zhao","year":"2011","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.bmc.2021.116497_b0115","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1021\/mp500781a","article-title":"Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985","volume":"12","author":"Elgersma","year":"2015","journal-title":"Mol Pharm"},{"issue":"5","key":"10.1016\/j.bmc.2021.116497_b0120","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0960-894X(03)00016-7","article-title":"An adjustable release rate linking strategy for cytotoxin\u2013Peptide conjugates","volume":"13","author":"Fuselier","year":"2003","journal-title":"Bioorg Med Chem Lett"},{"issue":"22","key":"10.1016\/j.bmc.2021.116497_b0125","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","article-title":"Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate","volume":"68","author":"Lewis Phillips","year":"2008","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.bmc.2021.116497_b0130","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.annonc.2019.11.019","article-title":"The art of innovation: clinical development of trastuzumab deruxtecan and redefining how antibody-drug conjugates target HER2-positive cancers","volume":"31","author":"Yver","year":"2020","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.bmc.2021.116497_b0135","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1248\/cpb.c18-00744","article-title":"The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy","volume":"67","author":"Nakada","year":"2019","journal-title":"Chem Pharm Bull (Tokyo)"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089621005058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089621005058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:15:38Z","timestamp":1760836538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089621005058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":27,"alternative-id":["S0968089621005058"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2021.116497","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Site-specific construction of triptolide-based antibody-drug conjugates","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2021.116497","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116497"}}